Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Heller
    Heller
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Danila
    Danila
  5. Fleisher
    Fleisher
  6. Kernan
    Kernan
  7. Morris
    Morris
  8. Eastham
    Eastham
  9. Herr
    Herr
  10. La Quaglia
    La Quaglia

Groups

  1. Biostatistics Service (24)
  2. Epidemiology and Biostatistics (24)
  3. Department of Medicine (20)
  4. Genitourinary Oncology Service (13)
  5. Solid Tumor Oncology Division (13)
  6. Pediatrics, Department of (9)
  7. GSK Faculty (8)
  8. Sloan Kettering Institute Faculty (8)
  9. Surgery (8)
  10. Tow Center for Developmental Oncology (TCDO) (7)
Search Within
  1. "Glenn Heller"
Formats
  1. Journal Article (16)
  2. Meeting Abstract (8)
Groups
  1. Biostatistics Service (24)
  2. Epidemiology and Biostatistics (24)
  3. Department of Medicine (20)
  4. Genitourinary Oncology Service (13)
  5. Solid Tumor Oncology Division (13)
  6. Pediatrics, Department of (9)

More Groups

People
  1. Glenn Heller (24)
  2. Howard Scher (11)
  3. Richard O'Reilly (5)
  4. Daniel Danila (4)
  5. Martin Fleisher (4)
  6. Michael Morris (4)

More People

Years
  1. 2021 (1)
  2. 2017 (2)
  3. 2014 (1)
  4. 2011 (1)
  5. 2009 (1)
  6. 2008 (1)

More Years

Publications
  1. Experimental Hematology (8)
  2. Urology (5)
  3. Journal of Urology (4)
  4. European Urology (3)
  5. Controlled Clinical Trials (1)
  6. International Journal of Infectious Diseases (1)

More Publications

Results (24)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)
    Journal Article

    Eastham, J. A.; Heller, G.; Hillman, D. W.; Hahn, O. M.; Parsons, J. K.; Mohler, J. L.; Small, E. J.; Morris, M.
    Journal of Urology (2021)

    Fulltext@MSK | Save
  • A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer
    Journal Article

    O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Touijer, K. A.; Morris, M. J.; Danila, D. C.; Laudone, V. P.; Bochner, B. H.; Sheinfeld, J.; Dayan, E. S.; more...
    Urology (2017)

    Fulltext@MSK | Save
  • Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer
    Journal Article

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
    European Urology (2017)

    Fulltext@MSK | Save
  • Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival
    Journal Article

    Danila, D. C.; Anand, A.; Schultz, N.; Heller, G.; Wan, M.; Sung, C. C.; Dai, C.; Khanin, R.; Fleisher, M.; Lilja, H.; more...
    European Urology (2014)

    Fulltext@MSK | Save
  • TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
    Journal Article

    Danila, D. C.; Anand, A.; Sung, C. C.; Heller, G.; Leversha, M. A.; Cao, L.; Lilja, H.; Molina, A.; Sawyers, C. L.; Fleisher, M.; more...
    European Urology (2011)

    Fulltext@MSK | Save
  • Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
    Journal Article

    Scher, H. I.; Jia, X.; de Bono, J. S.; Fleisher, M.; Pienta, K. J.; Raghavan, D.; Heller, G.
    Lancet Oncology (2009)

    Fulltext@MSK | Save
  • Effect of peri-transplant Linezolid on time to neutrophil and platelet engraftment after allogeneic stem cell transplantation (HSCT)
    Meeting Abstract

    Papanicolaou, G. A.; Cohen, N.; Mihu, C.; Jakubowski, A.; Pamer, E.; Chou, J.; Heller, G.
    International Journal of Infectious Diseases (2008)

    Fulltext@MSK | Save
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Androgen deprivation for minimal metastatic disease: Threshold for achieving undetectable prostate-specific antigen
    Journal Article

    Beekman, K.; Morris, M.; Slovin, S.; Heller, G.; Wilton, A.; Bianco, F.; Scardino, P. T.; Scher, H. I.
    Urology (2005)

    Fulltext@MSK | Save
  • Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Journal Article

    Ryan, C. J.; Zelefsky, M. J.; Heller, G.; Regan, K.; Leibel, S. A.; Scher, H. I.; Kelly, W. K.
    Urology (2004)

    Fulltext@MSK | Save